Antiplatelet agents for acute coronary syndrome: a review of the guidelines and recommendations
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001022
English
Authors' recommendations:
While clopidogrel is used to prevent ischemic events in NSTEMI and STEMI patients and prasugrel is given with ASA to prevent stent thrombosis, there is insufficient evidence to determine ticagrelors’ place in therapy in relation to these agents.
Details
Project Status:
Completed
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Acute Coronary Syndrome
- Platelet Aggregation Inhibitors
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.